Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enasidenib vs Conventional Care in IDH2-mutated Late Stage AML
NCT02577406Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2015
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of enasidenib in acute myeloid leukemia (AML), sponsored by Celgene Corporation. Started Dec 2015; status: completed.
02
Drugs
enasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02577406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02577406.